

DAFTAR PUSTAKA

- Akkoca M, Tokgoz S, Yilmaz B, Akinci M & Yilmazer D, 2017 Diagnosis and Treatment Approaches for Intraabdominal Masses in Adults. *Ankara Universitesi Tıp Fakultesi Mecmuasi*, 70(3):201-205.
- Alfonso J, Baeyens P, Bauer M, Boirie Y, Cederholm T, Landi F, Martin C, Michel JP, Rolland Y, Scheineider M, Topinkova E, Vaundewoude M & Zamboni M, 2010 Sarcopenia: European Consensus on Definition and Diagnosis. *Age and Ageing*, 39:412-423.
- Antonelli G, Gigante E, Lavarone M, Begini P, Sangiovanni A, Lannicelli E, Biondetti P, Pellicelli M, Miglioresi L, Marchetti P, Lampertico P & Marigani M, 2018 Sarcopenia is Associated with Reduced Survival in Patients with Advanced Hepatocellular Carcinoma Undergoing Sorafenib Treatment. *United European Gastroenterology Journal*, 6(7):1039-1048.
- Beard J, Officer A, de Carvalho I, Sadana R, Pot AM, Michel J, Llooyd-Sherlock P, Epping-Jordan J, Peeters G, Mahanani W, Thiyagarajan J & Chatterji S, 2016. The World Report on Ageing and Health: a Policy Framework for Healthy Ageing. *Lancet*, 387(10033):2145-2154.
- Begini P, Gigante E, Antonelli G, Carbonetti F, Lannicelli E, Anania G, Imperatrice B, Pellicelli M, Fave D & Marignani M, 2017 Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. *The Journal of the Mexican Association of Hepatology*, 16(1):107-114.
- Bruix J, Sherman M, Llovlet J, Beaugrand M, Lencioni R & Burroughs A, 2001. Clinical Management of Hepatocellular Carcinoma. Conclusion of the Barcelona-2000 AESL Conference. *Journal of Hepatology*, 53(3):1020-1022.
- Budihusodo U. Karsinoma Hati. Dalam: Siti Setiati, Idrus Alwi, Aru W. Sudoyo, Mercellus Simadibrata, Bambang Setiyohadi dan Ari Fahrial Syam. Buku Ajar Ilmu Penyakit Dalam. Ed IV-Jilid III. Jakarta: Interna Publishing 2014 .pp. 3040-3046.
- Carey E, Lai J, Wang C, Dasarathy S, Lobach I, Loaa A & Dunn M, 2017 A Multicentre Study to Define Sarcopenia in Patients with End-Stage Liver Disease. *Liver Transpl*, 23(5):625-633.
- Chen LK, Lee WJ, Peng LN, Liu LK, Arai H & Akhisita M, 2016 Recent Advances in Sarcopenia Research in Asia : 2016 Update from the Asian Working Group for Sarcopenia. *The society for Post Acute and Long Term Care Medicine*, 30:1-5.
- Chen, L. K., Woo, J., Assantachai, P., Auyeung, T. W., Chou, M. Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., Kojima, T., Kuzuya, M., Lee, J. S. W., Lee, S. Y., Lee, W. J., Lee, Y., Liang, C. K., Lim, J. Y., Lim, W. S., ... Arai, H. (2020). Asian Working Group for Sarcopenia: 2019 Consensus

- Update on Sarcopenia Diagnosis and Treatment. *Journal of the American Medical Directors Association*, 21(3), 300-307.e2.
<https://doi.org/10.1016/j.jamda.2019.12.012>
- Chindaprasirt J, 2015 Sarcopenia in Cancer Patients. *Asian Pacific Journal of Cancer Prevention*, 16:8075-8077.
- Christensen F, Jones W, Andersen L, Daugaard G, Rorth M & Hojman P, 2014 Musle dysfunction in Cancer Patients. *Annals of Oncology*, 25(5):947-958
- Culloh M, Malhi H, Dhaliwal A, Cooper C & Shah T, 2018 The Adverse Impact of Sarcopenia and Visceral Fat Deposition on the Course of Hepatocellular Carcinoma and the Role of Nutritional Interventions. *European Medical Journal*, 3(2):126-134.
- Dahlan MS, 2016. Besar sampel dalam penelitian kedokteran dan kesehatan. 4th edition, Jakarta: Epidemiologi Indonesia, 317-320.
- Dasarathy S & Merli M, 2016 Sarcopenia from Mechanism to Diagnosis and Treatment in Liver Disease. *Journal of Hepatology*, 65:1232-1244.
- Dodson R, Firoozmand A, Hyder O, Tacher V, Cosgrove D, Bhagat N, Herman J, Wolfgang C, Geschwind J, Kamel I & Pawlik T, 2013 Impact of Sarcopenia on Outcomes Following Intra-aretrial Therapy of Hepatic Malignancies. *Journal Gastrointest Surg*:17(12):2123-2132.
- Dorn David, Bryant Mary, Zarzour Jessica, Smith Kevin, Redden David, Saddekni Souhil, Gray Stephen, White Jared, Eckhoff Devin & Dubay Derek, 2014. Chemoembolization Outcomes for Hepatocellular Carcinoma in Cirrhotic Patients with Compromized Liver Function. *Hepato Pancreto Billiary Journal* (16): 648-655.
- El-Serag HB, 2011 Hepatocellular Carcinoma. *New England Journal Medicine*, 365(12):1118-1127.
- European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer, 2016 EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. *Journal of Hepatology*, 56:908-953.
- Ferlay J, Colombet M & Soerjomataram, 2018 Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2018. Lyon: International Agency for Research on Cancer/World Health Organization.
- Fujita M, Takahashi A, Hayashi M, Okai K, Abe K & Ohira H, 2017 Skeletal Muscle Volume Loss during Transarterial Chemoembolization Predicts Poor Prognosis in Patient with Hepatocellular Carcinoma. Department of Gastroenterology, Fukushima Medical University School of Medicine.
- Forner A, Galle P, Llovet J, Mazzaferro V, Piscaglia F, Raoul J, Schirmacher P & Vilgrain V 2018. EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. *Journal of Hepatology*, 69:182-236

- Galle RP, Tovoli F, Foerster F, Worns MA, Cucchetti A, Bolondi L, 2017. The treatment of intermediate stage tumors beyond TACE: from surgery to systemic therapy. *Journal of Hepatology* vol 67: 173-183.
- Gokcan H, Savas N, Oztuna D, Moray G, Boyvat F & Haberal M, 2015 Predictors of Survival in Hepatocellular Carcinoma Patients. *Ann Journal*, 20:596-603.
- Ha Y, Kim D, Han S, Chon E, Lee B, Kim N, Lee H, Park H, Rim S & Hwang G, 2018 Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function. *Cancer Research and Treatment*, 50(3):843-851.
- Han A, Bokshan L, Marcaccio E, DePasse M & Daniels H, 2018 Diagnostic Criteria and Clinical Outcomes in Sarcopenia Research: A Literature Review. *Journal of Clinical Medicine*, 7(70):1-11.
- Hirota K, Kawaguchi T, Hashida R, Koya S, Bekki M, Goshima N, Teruhito Y, Otsuka T, Nozoe R, Nakano D, Shirono T, Shimose S, Iwamoto H, Niizeki T, Matsuse H, Koga H, Shiba N & Torimura T, 2018 Profiles Associated with Sarcopenia in Hepatoma Patients Underwent Transcatheter Arterial Chemoembolization : A Data-Mining Analysis. *Journal of Cachexia, Sarcopenia and Muscle*, 3:1-17.
- Hull R, 2012 Relevance of Immobility and Importance of Risk Assessment Management for Medically Ill Patients. *Clinical and Applied Thrombosis/Hemostasis*, 19(3):268-276.
- Imai K, Takai K, Watanabe S, Hanai T, Suetsugu A, Shiraki M & Shimizu M, 2017 Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma : The Role of Liver Functional Reserve and Tumor-Related Factors of Loss of Skeletal Muscle Volume. *Nutrients*, 9:1054.
- Jindal A & Jagdish K, 2019 Sarcopenia: Ammonia Metabolism and Hepatic Encephalopathy. *Clinical and Molecular Hepatology*, 25:270-279.
- Kamachi S, Mizuta T, Otsuka T, Nakashita S, Ide Y, Miyoshi A, Kitahara K, Eguchi Y, Ozaki I & Anzai K, 2016 Sarcopenia is a Risk Factor for the Recurrence of Hepatocellular Carcinoma after Curative Treatment. *Hepatology Research*, 46:201-208.
- Kawaguchi T, Koya S, Hashida R, Hirota K, Bekki M, Goto E, Yamada M, Sugimoto M, Hayashi S, Goshima N, Yoshiyama T, Otsuka T, Nozoe R, Nagamatsu A, Nakano D, Shirono T, Shimose S, Iwamoto H, Niizeki T, Matsuse H, Koga H, Miura H, Shiba N & Torimura T, 2016 Effects of In-Hospital Exercise on Sarcopenia in Hepatoma Patients Who Underwent Transcatheter Arterial Chemoembolization. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine.
- Kim C, Kim H, Park J, Park D & Cho Y, 2014. Radiologic Response to Transcatheter Hepatic Arterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma. *Liver Cancer*, 34(2):305-312.

- Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, Sakamaki A, Kamimura K, Tsuchiya A, Takamura M, Yamagiwa S & Terai S, 2018 Rapidly Declining Skeletal Muscle Mass Predicts Poor Prognosis of Hepatocellular Carcinoma Treated with Transcatheter Intra-arterial Therapies. *BMC Cancer*, 18:756.
- Kohla MAS, Abu Zeid MI, Al-Warraky M, Taha H, Gish RG, 2015. Predictors of Hepatic Decompensation After TACE for Hepatocellular Carcinoma. *BMJ Open Gastroenterology*, 2:e000032.
- Kung J, MacDougall M, Madhavan K, Garden O & Parks R, 2006 Predicting survival in Patients with Hepatocellular Carcinoma: A UK Perspective. *The Journal of Cancer Surgery EJSO*, 33:188-194.
- Lanza E, Masetti C, Messina G, Muglia R, Pugliese N, Ceriani R, Nalda A, Rimassa L, Torzilli G, Poretti D, D'antuono F, Politi L, Pedicini V & Aghemo A, 2020 Sarcopenia as a Predictor of Survival in Patient Undergoing Bland Transarterial Embolization for Unresectable Hepatocellular Carcinoma. *Plos ONE* 15(6):e0232371, <https://doi.org/10.1371/journal.pone.0232371>.
- Loosen H, Schulze-Hagen M, Bruners P, Tacke F, Trautwein C, Kuhl C, Luedde T & Roderburg C, 2019 Sarcopenia is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. *Cancers MDPI*, 11:1-13.
- Loza M, 2014 Clinical Relevance of Sarcopenia in Patients with Cirrhosis. *World Journal of Gastroenterology*, 20(25):8061-8071.
- Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Nuemman P & Lurje G, 2019 Treatment Strategies for Hepatocellular Carcinoma-A Multidisciplinary Approach. *International Journal of Molecular Science*, 20:1465.
- Mardian Y, Yano Y, Ratnasari N, Choridah L, Wasityastuti W, Setyawan N & Hayashi Y, 2019 Sarcopenia and Intramuscular Fat Deposition are Associated with Poor Survival in Indonesian Patients with Hepatocellular Carcinoma: a Retrospective Study. *BMC Gastroenterology*, 19(229):1-11.
- Marrero Ja & Welling T 2009. Modern Diagnosis and Management of Hepatocellular Carcinoma. *Clin Liv Dis*, 13:233-247.
- Mufida, AZ, 2018. Prediktor Survival Tiga Bulan Pasien Karsinoma Hepatoseluler yang Menjalani Transarterial Chemoembolization Konvensional. Departemen Ilmu Penyakit Dalam. Fakultas Kedokteran-Universitas Airlangga.
- Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Kamekado H, Nishimura T, Kita R, Kimura T, Ijima H, Nishiguchi S & Osaki Y, 2017 Prognostic Significance of Sarcopenia in Patients with Hepatocellular Carcinoma Undergoing Sorafenib Therapy. *Oncology Letters*, 14:1637-1747.

- Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K & Nishiguchi S, 2016 JSH (Japan Society Hepatology) Guidelines for Sarcopenia in Liver Disease (First Edition): Recommendation from The Working Group for Creation of Sarcopenia Assessment Criteria in the JSH. Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine.
- Nuttall F, 2015 Body Mass Index; Obesity, BMI and Health: A Critical Review. *Nutritional Research*, 50(3):117-128.
- O'Brien, & Williams. (2008). Nutrition in end stage liver diseases principles (2 ed.).
- Omata M, Cheng A, Kokudo N, Kudo M, Lee J, Jia J, Tateishi R, Han K, Chawla Y, Shiina S, Jafri W, Payawal D, Ohki T, Ogasawara S, Chen P, Lesmana C, Lesmana L, Gani R, Obi S, Dokmeci A & Sarin S, 2017 Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: a 2017 Update. *Hepatol Int*, 11:317-370.
- Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, 2015. A Prognostic Score for Patients with Intermediate – Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. *PloS ONE* 10 (4).
- Perhimpunan Peneliti Hati Indonesia, 2017. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta: PPHI.
- Peterson J & Braunschweig, 2015 Prevalence of Sarcopenia and Associated Outcomes in the Clinical Setting. *Nutrition in Clinical Practice*, 20(10):1-9.
- Pramudya D. 2016 Prediktor Kejadian Non-Responder Pada Pasien Karsinoma Hepatoseluler yang Dilakukan Tindakan TACE. Karya Akhir Program Pendidikan Dokter Spesialis Ilmu Penyakit Dalam, Universitas Airlangga, Suarabaya, Indonesia
- Quinto MA, Nutu O, Manso R, Alonso I, Pulido J, Municio A, Sesma A, Segurolo C, Caballero J & Romero L, 2018 Complication of Transarterial Chemoembolization (TACE) in the Treatment of Liver Tumors. *CIR ESP*, 96(9):560-567.
- Raphael W, Yangde Z & Yuxiang C, 2012 Hepatocellular Carcinoma: Focus on Different Aspects of Management. *International Scholarly Research and Network Oncology*, 1-12.
- Restu AP, 2019. Skala Albumin-Bilirubin Sebagai Faktor Pediktor Kesintasan 3 Bulan Pasien Karsinoma Sel Hati Setelah Transarterial Chemoembolization Pertama. Departemen Ilmu Penyakit Dalam. Fakultas Kedokteran-Universitas Airlangga.
- Rohmah NS, Ratnasari N & Bayupurnama P, 2019 Barcelona Clinic Liver Cancer (BCLC) Staging Sebagai Prediktor Mortalitas Pada Pasien Karsinoma Hepatoseluler Dengan atau Tanpa Sarkopenia.
<http://etd.repository.ugm.ac.id/>

- Sawhney S, Montano-Loza A, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R. Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Predictors of Survival. *Canadian Journal of Gastroenterology*, 25(8):426-432.
- Sergi, G., De Rui, M., Veronese, N., Bolzetta, F., Berton, L., Carraro, S., Bano, G., Coin, A., Manzato, E., & Perissinotto, E. (2015). Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. *Clinical Nutrition*, 34(4):667–673. <https://doi.org/10.1016/j.clnu.2014.07.010>
- Sevastianos V & Dourakis S, 2016 Malnutrition and Sarcopenia in Advanced Liver Disease. *Journal Nutrition Food Sci*, 6(2):1-8.
- Schutte K, Schulz C & Malfertheiner P, 2015 Nutrition and Hepatocellular Cancer. *Gastrointestinal Tumors*, 2:188-194.
- Schutte K, Tippelt B, Schulz C, Rohl F, Feneberg A, Seidensticker , Arend J & Malfertheiner M, 2014 Malnutrition is a prognostic Factor in Patients with Hepatocellular Carcinoma. *Clinical Nutrition*, 30:1-6.
- Schulz C et al, 2016. Nutrition and Hepatocellular Cancer. *Gastrointest Tumors*, 2(4):188–194.
- Schwartz J and Carithers R, 2017. Clinical Features and Diagnosis of Primary Hepatocellular Carcinoma.Update [online]. Tersedia di: <https://www.update.com/contents/clinical-features-and-diagnosis-of-primary-hepatocellular-carcinoma> [Diakses pada 20 Desember 2019].
- Shi L, Feng Y, Lin H, Ma R & Cai X, 2014 Role of Estrogen in Hepatocellular Carcinoma: is Inflammation the Key?. *Journal of Translation Medicine*, 12:93.
- Sinha T, 2018 Tumors: Benign & Malignant. *Cancer Therapy and Oncology International Journal*, 10(3):1-3.
- Song S, 2018 Sarcopenia: Definition and Measurement. *Recent Update in Cirrhosis and Sarcopenia*, 410-415.
- Tanriverdi O, 2014 A Discussion of Serum Albumin Level in Advanced Stage Hepatocellular Carcinoma: A Medical Oncologist's Perspective. *Med Oncol*, 31(282):1-5.
- Villanueva A, 2019 Hepatocellular Carcinoma. *The New England Journal of Medicine*, 380:1450-1462.
- Yuen M, Hou J & Chutaputti A, 2009 Hepatocellular Carcinoma in the Asia Pasific Region. *Journal of Gastroenterology and Hepatology*, 24:346-353.
- Waghray A, Murali R & Menon N, 2015 Hepatocellular Carcinoma: From Diagnosis to Treatment. *World Journal of Hepatology*, 7(8):1020-1029.

- Waller P, Deshpande V & Pysopoulos N, 2015 Hepatocellular Carcinoma: A Comprehensive Review. *World Journal of Hepatology*, 7(26):2648-2663.
- Walter et al, 2011. A Practical Guide to Bioelectrical Impedance Analysis Using the Example of Chronic Obstructive Pulmonary Disease. *Nutrition Journal*. 10.1186/1475-2891-10-35.
- Wu E, Wong L, Hernandez B, Ji J, Jia W, Kwee S & Kalathi S, 2018 Gender Differences in Hepatocellular Cancer: Disparities in Nonalcoholic Fatty Liver Disease/Steatohepatitis and Liver Transplantation. *Hepatoma Res*, 4:1-17.
- WHO, 2016. What is malnutrition? <https://www.who.int/features/malnutrition/en/>
- Zhu R, Seto W, Lai C & Yuan M, 2016 Epidemiology of Hepatocellular Carcinoma In the Asia Pacific Region. *Gut & Liver*, 10:332-339.